Project Grant HT94252410630

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625.00 to the University of Pittsburgh to develop a novel nanocarrier-based immunochemotherapy for the treatment of metastatic colorectal cancer (mCRC). The key products and services to be delivered include: Developing and characterizing a nanoparticle carrier capable of co-delivering small interfering RNA targeting the IRHOM1 protein and a prodrug conjugate of...

This Project Grant award of $421,685 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas MD Anderson Cancer Center aims to investigate how the LIFR-LCN2 pathway in liver cancer suppresses the cytotoxic function of CD8+ T cells, leading to immune evasion and resistance to immunotherapy. The research project has two specific aims: 1) to investigate whether the LIFR-LCN2 pathway inhibits the effector function of CD8+ T cells, and 2) to determine...

This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $333,504 to The Washington University to conduct research on the role of peritoneal myeloid cells in colorectal cancer peritoneal metastasis and implications for immunotherapy. The award commences on July 1, 2025 and is scheduled for completion by July 31, 2027. The key objectives of this research project are to: Profile immune cell phenotypical changes in the peritoneal fluid and...

This federal Project Grant award of $636,222 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the University of Pittsburgh to investigate how immune checkpoint inhibitor-associated gut bacteria can modulate tumor immunity and enhance the efficacy of immune checkpoint inhibitor (ICI) therapy in melanoma. The key goals of the research are to: 1) Determine whether ICI-associated bacteria metabolize dietary tryptophan into aryl...

This Cooperative Agreement award from the National Cancer Institute, a division of the Department of Health and Human Services, provides $380,509 under the Cancer Biology Research program to The Trustees of Columbia University in New York. The award supports research to elucidate the molecular drivers of melanoma liver metastasis and associated resistance to immunotherapies. Specifically, the researchers will characterize a novel preclinical mouse model that recapitulates genomic and...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Cold Spring Harbor Laboratory provides $640,583 to enhance the efficacy of immunotherapy against metastatic colorectal cancer. The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their metabolic fitness and anti-tumor activity within the tumor microenvironment. The research aims to delineate the mechanisms by which PPARD activation improves CD8+ T cell...

The National Cancer Institute (NCI), under the federal Cancer Research Manpower (CFDA 93.398) program, awarded a $270,981 Project Grant to The University of Texas Southwestern Medical Center (UT Southwestern) to conduct research on immunotherapy resistance mechanisms and targeting the TIGIT immune checkpoint in hepatobiliary cancers. The 5-year grant will support a research program encompassing a Phase 2 clinical trial of an anti-TIGIT plus anti-PD-1 antibody regimen, characterization of...

This federal Project Grant award, with an ID of R01CA294704, was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Mayo Clinic for the project "Radiation and Dendritic Cell Combination to Improve Immunotherapy Response in Intrahepatic Cholangiocarcinoma". The $610,890 award, effective September 1, 2024 through August 31, 2029, will support a two-part research study. The first aim is to assess the clinical efficacy of combining external beam...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $460,985 to The Ohio State University to develop a novel therapeutic strategy to target liver metastasis in colon cancer patients. The key objectives are to determine the efficacy of using dopamine D4 receptor agonists, alone or in combination with anti-cancer drugs, to prevent or reduce the incidence of liver metastasis in preclinical animal models. The research will also...

The National Cancer Institute (NCI) awarded a 3-year, $183,398 Project Grant to The Ohio State University under the Cancer Research Manpower (CFDA 93.398) program. The goal of the project is to elucidate the mechanisms by which tumor hypoxia (low oxygen) contributes to immune privilege and treatment resistance in non-small cell lung cancer (NSCLC) tumors. The researchers will investigate the use of mitochondrial inhibitors, such as papaverine (PPV) and SMV-32, to reoxygenate the NSCLC tumor...